Antiemetic therapy - Aphios Corporation
Alternative Names: Ginger extract - Aphios; ZindolLatest Information Update: 25 Nov 2021
Price :
$50 *
At a glance
- Originator Aphios Corporation
- Developer Aphios Corporation; University of Rochester; Zindol LLC
- Class Antiemetics; Kampo medicine; Traditional Chinese medicine
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Chemotherapy-induced nausea and vomiting
Most Recent Events
- 25 Nov 2021 Phase-III clinical trials in Chemotherapy-induced nausea and vomiting (Adjuvant therapy) in USA (PO) in November 2021 (Aphios Corporation pipeline, November 2021)
- 05 Apr 2021 Phase II/III development is still ongoing in USA (Aphios Corporation pipeline, April 2021)
- 01 Apr 2021 Aphios Corporation intends to file NDA to the US FDA in Chemotherapy-induced nausea and vomiting (Aphios Corporation pipeline, April 2021)